Navigation Links
BioVex Raises $40 Million in First Close of Series F Financing
Date:3/30/2009

WOBURN, Mass., March 30 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it has raised $40 million in the first close of a series F private financing.

The placement was led by Forbion Capital Partners, who were joined by other existing investors including Credit Agricole Private Equity, Harris & Harris Group, Innoven Partners, New Science Ventures, Triathlon Medical Venture Partners and Scottish Equity Partners.

Philip Astley-Sparke, President & CEO for BioVex Inc said:

"Following the unprecedented number of durable complete remissions generated with our lead cancer product, OncoVEX GM-CSF in a Phase II study in metastatic melanoma, the funds will be used to commence a pivotal Phase III study. The Board is currently examining a number of options to raise a further $20 million to fund preparations for a BLA filing following the generation of Phase III data in 2010."

The Phase III study design agreed with the FDA under a Special Protocol Assessment (SPA) follows directly from the study design successfully employed in Phase II. The Phase III study will also enroll previously treated patients with unresectable Stage IIIc and Stage IV disease using OncoVEX GM-CSF as monotherapy. Stage IIIb patients will also be eligible. The primary efficacy endpoint will also be response rate-based; the primary objective being to demonstrate a statistically significant increase in the rate of objective responses maintained for six months or more, in comparison to control therapy (subcutaneously administered GM-CSF). The study is intended to enroll 360 evaluable patients randomized such that 240 patients receive OncoVEX GM-CSF and 120 patients receive control. BioVex plans to begin enrolling patients for the Phase III study in the second quarter of 2009.

'/>"/>
SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioVex to Present at the UBS Global Life Sciences Conference
2. BioVex Closes Second Round of Series E Financing
3. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
4. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
5. Moodys Raises Boston Scientifics Rating Outlook to Stable
6. GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners
7. Eiger BioPharmaceuticals Raises $7.1 Million A Round
8. NanoBio Corporation Raises $12 Million in Series B Financing
9. Divergence Raises $11.8 Million in Series C Financing
10. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
11. AMERIGROUP Praises Expansion of State Childrens Health Insurance Program (SCHIP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
(Date:8/21/2014)... KONG , Aug. 21, 2014  China Cord Blood ... announced its plan to release financial results for the ... 28, 2014, after market close in the US.  ... at 8:00 a.m. ET on Friday, August 29, 2014 ... overview of the Company,s recent developments, followed by a ...
(Date:8/21/2014)... VIEW, Calif. , Aug. 21, 2014 /PRNewswire/ ... properties and behaviors based on external stimuli such ... poised to have a disruptive effect in multiple ... revolutionize the business landscape by printing objects ranging ... aerospace and automotive sectors. Logo - ...
(Date:8/21/2014)... Pursuit Solutions ( http://www.pursuit-solutions.com ), a ... for Life Sciences sales and marketing organizations, announced ... Commercial Sales Models” by Peter Robinson, co-founder and ... examines some innovative models used to improve sales ... the pharmaceutical market. Robinson grades the industry on ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... China, April 8 Sinobiopharma Pharmaceutical Group (OTC ... appointment of Ms. Yan Tan as Director of ... Ltd., Netherlands. She served as a China-based Unit ... to Schering-Plough. Prior to Organon, Ms. Tan held ...
... the simplicity of protein precipitation with the ... of phospholipids and proteins from biological samples ... Supelco, a division of Sigma-Aldrich (Nasdaq: ... supplier of chromatography products for analysis and ...
... April 8 ImQuest Life Sciences presented their ... their novel small molecule piperazine compound for the ... Therapeutics meeting held in Whistler, British Columbia. The ... lead microtubule inhibitor, IQP-0304. The piperazines demonstrate potent ...
Cached Biology Technology:Sinobiopharma, Inc. Appoints New Director of Marketing 2HybridSPE(TM)-Precipitation Technology Wins SelectScience.net 2009 Scientists' Choice Award for Best New Separations Product in 2008 2HybridSPE(TM)-Precipitation Technology Wins SelectScience.net 2009 Scientists' Choice Award for Best New Separations Product in 2008 3ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program 2
(Date:8/21/2014)... New feeding tube connectors, designed by an international standards ... safety. , According to an invited review published in ... ( NCP ), the official journal of the ... new connectors will greatly reduce the occurrence of misconnection ... , Small-bore connectors, which are used to join medical ...
(Date:8/21/2014)... researchers at Louisiana Tech University has developed ... 3D printers and materials to fabricate custom ... chemotherapeutic compounds for targeted drug delivery. , ... research faculty from Louisiana Tech,s biomedical engineering ... filament extruders that can make medical-quality 3D ...
(Date:8/21/2014)... Australian National University (ANU) team has successfully replicated one ... for biological systems powered by sunlight which could manufacture ... so is sunlight. It is an exciting prospect to ... and safely," said Dr Kastoori Hingorani, from the ARC ... Research School of Biology. , Hydrogen offers potential as ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Water and sunlight the formula for sustainable fuel 2
... Who:, , Nobel Laureate Martin Chalfie of Columbia ... Incoming ASCB president Sandra Schmid of Scripps Research Institute, ... as moderator What: An informal, good-natured, and ... format, this experimental program will be targeted to young ...
... 2010 The human body is home to a complex ... in both health and disease. Viruses can attack and ... about how this might influence human health. In a ... www.genome.org ), scientists have performed the first metagenomic analysis of ...
... with type 1 diabetes may be able to grow ... Georgetown University Medical Center (GUMC) researchers who presented their ... 50th annual meeting in Philadelphia. Their laboratory and animal ... stem cells (SSCs) extracted from testicular tissue can morph ...
Cached Biology News:Tracing microbes between individuals towards personalized oral health care 2'Grow your own transplant' may be possible for men with type 1 diabetes 2
... Cell Dissociation Buffers are membrane-filtered isotonic ... chelating agents and cell-conditioning agents in ... salt solution or Ca2+- and ... of mammalian cells from support substrates ...
Request Info...
Request Info...
...
Biology Products: